SCOTTSDALE, Ariz., Aug. 11, 2006 (PRIMEZONE) -- Motion DNA Corporation (Pink Sheets:MTDX) today has announced an addition to its licensing program to major corporations in the medical, fitness, and sports fields.
Under a new licensing plan, customers who desire a specific product for their market may contract with Motion DNA to develop a specific product. For example, any manufacturer who wants motion capture software to assist in the promotion of their company or a specific product may hire Motion DNA to develop and assist in the distribution of the product.
The company has identified and opened discussions over the last several months with major manufacturers who desire Motion DNA-like products in sports, medicine, retail, and other areas.
Licensing fees start at $100,000 for small niche markets and range as high as $1,000,000 for major markets based upon the potential size of the market. Licensees will also pay MTDX up 10% royalties on all product sales from the licensee.
"So far, in just the last four weeks since the conception of this program, we have received very strong indications of interest from dozens of potential 'partners,' the names of which will be released as they come aboard over the next few weeks," according to Motion DNA's Founder, Zig Ziegler. "This is a great new major revenue stream and moves us categorically into a different income potential."
Over the past twelve months, Motion DNA has worked on contracts with professional sports teams and leagues and attempted to sell products and services to major companies.
"We are viewed as a small fish with very little credibility," added Ziegler. "We have identified that we need stronger partners to create mass acceptance in the market place, with our product as the foundation underneath someone else's branding."
Motion DNA writes software customizable for any company's needs with respect to motion testing. Motion DNA expects to sign and be able to deliver upon up to four contracts per year.
To reiterate yesterday's news: Ziegler announced that MTDX was "very close" to receiving three multi-million dollar purchase orders, as a direct result of exhibiting Motion DNA's BioCap(r) and BioCap(r) motion analysis system in Washington, D.C. three weeks ago.
Utilizing the latest motion-capture technology, BioCap(r) is Motion DNA's most advanced human movement analysis system available. BioCap(r) allows testing professionals to turn any activity into a test with measurable and comparative results. Real-time biomechanical testing of 3-D angles, velocities, rotations and positions are measured and recorded, providing valuable data on athletic activity.
About Motion DNA Corporation
Based in Scottsdale, Arizona, Motion DNA has developed state-of-the-art products and services that incorporate advanced 3-D motion-capture technology, which provides diagnostic testing for individual athletes, medical professionals and sports organizations. These types of analyses are designed to identify physical limitations related to strength, mobility, coordination and biomechanics.
The Motion DNA Corporation logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2484
Forward-looking Statements:
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.